Claim

In adults with rheumatoid arthritis, psoriatic arthritis, or related autoimmune disease receiving low-dose methotrexate, a model combining baseline hepatic steatosis and obesity/metabolic dysfunction will predict persistent transaminitis and fibrosis-signal escalation more accurately than cumulative methotrexate dose alone.

Why this matters

Methotrexate remains a cornerstone therapy, but liver monitoring is still often framed around cumulative dose thresholds. Recent cohort and review data suggest that the clinically important substrate is frequently metabolic liver vulnerability: steatosis, obesity, and diabetes. If true, current monitoring logic is underweighting the variables most likely to identify who actually needs early escalation.

Mechanistic rationale

• Methotrexate-associated liver injury in modern low-dose autoimmune practice appears to ride on pre-existing fatty liver more often than on dose alone.
• Obesity and diabetes increase the probability that simple steatosis will progress to inflammatory or fibrotic liver injury.
• Therefore, the interaction between baseline steatosis and metabolic burden should outperform cumulative dose as a predictor of persistent enzyme elevation.

Testable prediction

In a prospective multicenter cohort with baseline ultrasound or transient elastography:

1. A model using only cumulative methotrexate dose will show lower discrimination for 12-month persistent transaminitis than a model adding steatosis, BMI, and diabetes.
2. The strongest effect will be seen in patients with known NAFLD and BMI >=30 kg/m2.
3. Patients with high cumulative dose but no steatosis/metabolic disease will have lower realized event rates than patients with moderate dose and clear metabolic liver risk.

Proposed study

• Population: adults with RA, PsA, or other autoimmune disease starting or continuing methotrexate
• Baseline variables: BMI, diabetes, steatosis by imaging, alcohol exposure, viral hepatitis, folate use
• Outcomes: persistent transaminitis, methotrexate interruption, non-invasive fibrosis progression
• Analysis: nested logistic/time-to-event models; compare AUROC, calibration, and decision-curve net benefit

Falsifiability

This hypothesis fails if cumulative dose alone performs as well as or better than models incorporating baseline steatosis and metabolic risk.

Limitations

• Imaging access varies across sites.
• Alcohol exposure and concomitant hepatotoxins may be misclassified.
• Disease activity and co-medications can still confound liver tests.

References

1. Mori S, et al. Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study. Rheumatol Adv Pract. 2020;4:rkaa020. DOI: 10.1093/rap/rkaa020
2. Lindsay K, et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford). 2009;48:569-572. DOI: 10.1093/rheumatology/kep023
3. Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018;8:21-29. DOI: 10.2147/PTT.S141629